Education
About Us
Working with TipRanks
Follow Us
JOEL LEWIS Insider Profile
4 Followers
JOEL LEWIS, President & CEO, Director at Galectin Therapeutics, holds 778.26K shares in Galectin Therapeutics (Ticker: GALT). Most recently, JOEL LEWIS Sold 56,332 shares of Galectin Therapeutics on Jan 13, 2026 for an estimated value of $218.57K.
JOEL LEWIS Galectin Therapeutics (GALT)President & CEO, Director
Galectin Therapeutics (GALT)
President & CEO, Director
Ranked #96,705 out of 105,518 Corporate Insiders
Profitable Transactions
1 out of 7 Profitable Transactions
Average Return
-35.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
President & CEO, Director
Roles that JOEL LEWIS holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Feb 21, 2023 - Feb 21, 2024
Return:+16.20%
The most profitable trade made by JOEL LEWIS
JOEL LEWIS's Trading History
List of latest transactions for each holding click on a transaction to see JOEL LEWIS's performance on stock
You May Also Like
JOEL LEWIS insider profile FAQ
What is the percentage of profitable transactions made by JOEL LEWIS?
The percentage of profitable transactions made by JOEL LEWIS is 14%.
What is the average return per transaction made by JOEL LEWIS?
The average return per transaction made by JOEL LEWIS is -35.80%.
What stocks does JOEL LEWIS hold?
JOEL LEWIS holds: GALT stocks.
What was JOEL LEWIS’s latest transaction?
JOEL LEWIS latest transaction was an Informative Sell of $218.57K.
What was JOEL LEWIS's most profitable transaction?
JOEL LEWIS’s most profitable transaction was an Informative Buy of GALT stock on February 21, 2023. The return on the trade was 16.20%.
What is JOEL LEWIS's role in Galectin Therapeutics?
JOEL LEWIS's role in Galectin Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.